Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents-Reference-Cited by-同舟云学术

Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

Published:2016-10-14 Issue:4 Volume:123 Page:629-637
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Jabbour Elias¹,Faderl Stefan¹,Sasaki Koji¹,Kadia Tapan¹,Daver Naval¹,Pemmaraju Naveen¹,Patel Keyur²,Khoury Joseph D.²,Bueso‐Ramos Carlos²,Bohannan Zachary¹,Ravandi Farhad¹,Borthakur Gautam¹,Verstovsek Srdan¹,Miller Darla¹,Maduike Rita¹,Hosing Chitra³,Kantarjian Hagop M.¹,Garcia‐Manero Guillermo¹

Affiliation:

1. Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas

2. Department of HematopathologyThe University of Texas MD Anderson Cancer CenterHouston Texas

3. Department of Stem Cell TransplantationThe University of Texas MD Anderson Cancer CenterHouston Texas

Funder

Edward P. Evans Foundation

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.30383